Abiopharma

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition

Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones

Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Castle Biosciences - Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

Cerus Corporation - Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook